Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa trial of NVG-222 in solid tumours
ISRCTN13633989Phase 2Not yet recruiting
- Sponsor
- Cancer Research UK
- Start
- Jan 2027
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of NVG-222 in Nonhematologic neoplasms (3 arms), sponsored by Cancer Research UK. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose / optimal biological dose / therapeutic dose range / optimal dose schedule and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
NVG-222
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ISRCTN13633989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13633989.